The latest news & events

Keep up to date with company updates, industry news, investor
press releases and event information.

Events : 4 Oct 2018

Kneat to support ISPE Life Sciences 4.0, Limerick, Ireland

Join us at Life Sciences 4.0, October 18  Life Sciences 4.0 takes place in Limerick, Ireland The next in ISPE’s…

Read More
Events : 12 Sep 2018

Kneat to return to US Validation Week 2018 in San Diego

Join us at IVT US Validation Week 2018, October 22-24     IVT’s 24th Annual Validation Week will offer four tracks —…

Read More
Events : 12 Sep 2018

Kneat to exhibit at 2018 PDA-FDA Joint Regulatory Conference

Join us at the 2018 PDA-FDA Joint Regulatory Conference, September 24-26    The PDA/FDA Joint Regulatory Conference is now in its…

Read More
Events : 12 Sep 2018

Kneat tier one client to present at BioTalk 2019

Join us at BioTalk 2019, September 19-20, Titanic Chaussee Berlin BioTalk is a leading annual meeting which brings together some…

Read More
Investor News - General : 22 Aug 2018

Tier One Customer Scaling Kneat’s Platform to New Processes

HALIFAX, August 22, 2018/CNW/ – kneat.com, inc. (TSX-V: KSI) (“Kneat”) is pleased to announce that another of its tier one pharmaceutical customers is expanding their use of Kneat’s software platform. The first contract with this customer was announced in February 2018.

Read More
Investor News - General : 23 Jul 2018

Kneat Customer Purchases Additional Licenses

HALIFAX, July 23, 2018/CNW/ – kneat.com, inc. (TSX-V: KSI) (“Kneat”) is pleased to announce that one of its customers has further expanded its user base of the Kneat Gx platform by purchasing additional on-premise licenses. This order represents a twenty-eight percent increase in licenses purchased

Read More
Investor News - General : 16 Jul 2018

Multinational Pharmaceutical Manufacturer selects Kneat

HALIFAX, July 16, 2018/CNW/ – kneat.com, inc. (TSX-V: KSI) (“Kneat”) is pleased to announce that it will be deploying its Software as a Service (“SaaS”) platform for the biotechnology division of a multinational pharmaceutical manufacturer with more than 70 manufacturing sites worldwide.

Read More
Investor News - General : 12 Jul 2018

Kneat Contracts with Global Healthcare Company

HALIFAX, July 12, 2018/CNW/ – kneat.com, inc. (TSX-V: KSI) (“Kneat”) is pleased to announce its fourth new top tier customer win of 2018. One of the world’s leading research-based developers of pharmaceuticals has chosen Kneat’s technology to digitize its commissioning, qualification and validation

Read More
Investor News - General : 14 Jun 2018

Leading Global Biotech Selects Kneat

HALIFAX, June 14, 2018 /CNW/ –  kneat.com , inc. (TSXV: KSI) (“Kneat”) is pleased to announce a new customer win. This customer, a global leader in biotechnology, is deploying Kneat’s software to a number of their sites after successfully completing product trials at an initial test site.

Read More
Investor News - General : 10 Apr 2018

kneat.com, inc. Announces Closing Of $6.185 Million Brokered Private Placement

HALIFAX, April 10, 2018 –  kneat.com , inc. (TSX-V: KSI) (“ Kneat ” or the “ Company ”) is pleased to announce that it has closed its previously announced brokered private placement for aggregate gross proceeds of $ $6,184,647 (the “Offering”), which was increased from the previously announced

Read More
Investor News - General : 27 Mar 2018

Kneat Announces Expansion of Sales Team in The United States

HALIFAX, March 27, 2018 – kneat.com, inc. (TSX-V: KSI) (“Kneat” or the “Company”) announces the appointment of Mr. Camilo Ruan as Director of Sales for the western region of the United States. Mr. Ruan has considerable experience selling enterprise software and will focus his efforts on a region

Read More
Investor News - General : 12 Mar 2018

Kneat.com Announces $5 Million Brokered Private Placement

HALIFAX, March 12, 2018 –  kneat.com , inc. (TSX-V: KSI) (“ Kneat ” or the “ Company ”) is pleased to announce that it intends to complete a brokered private placement for aggregate gross proceeds of up to $5.0 million (the “Offering”). The Company intends to issue 5,555,556 common shares at an

Read More

Sign Up to Our Newsletter

Contact

Talk to us

Find out how Kneat can make your validation easier, faster, and smarter.
Start your paperless validation revolution by speaking to our experts.

Europe: +353-61-203826
U.S: +1 888 88 KNEAT
Canada: +1 902 706 9074